Clinical Trials Browser

Alzheimer Disease, Amyloidosis, Amyotrophic Lateral Sclerosis, Anemia, Sickle Cell, Cystic Fibrosis, Ehlers-Danlos Syndrome, Gaucher Disease, Glycogen Storage Disease Type II, Huntington Disease, Myasthenia Gravis, Gangliosidosis, GM1, alpha-Thalassemia, beta-Thalassemia, Muscular Dystrophy, Duchenne, Insomnia, Fatal Familial, Rare Diseases

NCT04176211 2024-06-03

The Impact of Myasthenia Gravis in the Real World

Completed

2,847 enrolled

Autoimmune Diseases, Myasthenia Gravis, Nervous System Diseases, Neuromuscular Diseases, Autoimmune Diseases of the Nervous System, Neuromuscular Junction Diseases

NCT05635266 2024-05-07

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Recruiting

20,000 enrolled

Classical hematologyGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cell

red meat allergy, Alopecia Areata, Alzheimer Disease, Amyloidosis, Anemia, Sickle Cell, Arthritis, Asthma, Autistic Disorder, Behcet Syndrome, Celiac Disease, Colitis, Ulcerative, Crohn Disease, Cystic Fibrosis, Dermatitis, Atopic, Diabetes Mellitus, Epilepsies, Myoclonic, Fibrosis, Fibromyalgia, Graves Disease, Heart Diseases, Hepatitis, Hypersensitivity, Kidney Diseases, Leukemia, Lupus Erythematosus, Systemic, Lymphoma, Macular Degeneration, Multiple Sclerosis, Myasthenia Gravis, Neoplasms, Parkinson Disease, Pemphigus, Psoriasis, Schizophrenia, Spondylitis, Ankylosing, Thyroid Diseases, Vasculitis, Vitiligo, beta-Thalassemia, Hidradenitis Suppurativa, Hepatitis, Autoimmune, Stroke, Pulmonary Disease, Chronic Obstructive, Scleroderma, Diffuse

NCT04590716 2021-07-29

Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares

Completed

113 enrolled

Myasthenia Gravis

Clinical Trials

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

MG Cohort

MG-ARCADIA

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Detecting Fatigue From Voice in Generalised Myasthenia Gravis

BioDigit MG-03

BioDigit MG-02

VRMG

Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

The Impact of Myasthenia Gravis in the Real World

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares